Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Conditions
Keywords
lymphoma, cohort, serum, cell-free DNA
Brief summary
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Detailed description
The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows. 1. Registration after informed consent. 2. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood 3. Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood 4. Regular monitoring disease status and update of survival status 5. Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood
Interventions
DRUGChemotherapy
Systemic chemotherapy with curative intent
Sponsors
Samsung Genomic Institute
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas 2. 20 years 3. Patients requiring systemic chemotherapy with curative intent 4. Written informed consent
Exclusion criteria
1. Myeloid malignancy 2. Multiple myeloma 3. Patients do not require systemic chemotherapy with curative intent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response rate | 3 months after chemotherapy | response to chemotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | 3 year | Time to relapse/progression or any kinds of death |
| Overall survival | 3 year | Time to any kinds of death |
| Biomarker | 3 year | Development of biomarker predicting response and survival outcome |
Countries
South Korea
Contacts
Primary ContactSeok Jin Kim, MD, PhD
Outcome results
None listed